AU2008336295B2 - Improved immunizing composition - Google Patents

Improved immunizing composition Download PDF

Info

Publication number
AU2008336295B2
AU2008336295B2 AU2008336295A AU2008336295A AU2008336295B2 AU 2008336295 B2 AU2008336295 B2 AU 2008336295B2 AU 2008336295 A AU2008336295 A AU 2008336295A AU 2008336295 A AU2008336295 A AU 2008336295A AU 2008336295 B2 AU2008336295 B2 AU 2008336295B2
Authority
AU
Australia
Prior art keywords
protein
seq
polypeptide
amino acid
equi
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2008336295A
Other languages
English (en)
Other versions
AU2008336295A1 (en
Inventor
Jan-Ingmar Flock
Margareta Flock
Lars Frykberg
Bengt Guss
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intervacc AB
Original Assignee
Intervacc AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intervacc AB filed Critical Intervacc AB
Publication of AU2008336295A1 publication Critical patent/AU2008336295A1/en
Assigned to INTERVACC AB reassignment INTERVACC AB Amend patent request/document other than specification (104) Assignors: Bengt, Guss, Jan-Ingmar, Flock, Lars, Frykberg, Margareta, Flock
Assigned to INTERVACC AB reassignment INTERVACC AB Amend patent request/document other than specification (104) Assignors: Bengt, Guss, Jan-Ingmar, Flock, Lars, Frykberg, Margareta, Flock
Priority to AU2013205101A priority Critical patent/AU2013205101A1/en
Application granted granted Critical
Publication of AU2008336295B2 publication Critical patent/AU2008336295B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2008336295A 2007-12-13 2008-12-12 Improved immunizing composition Ceased AU2008336295B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2013205101A AU2013205101A1 (en) 2007-12-13 2013-04-13 Improved immunizing composition

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US1349507P 2007-12-13 2007-12-13
US61/013,495 2007-12-13
US8228108P 2008-07-21 2008-07-21
US61/082,281 2008-07-21
PCT/SE2008/051445 WO2009075646A1 (en) 2007-12-13 2008-12-12 Improved immunizing composition

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2013205101A Division AU2013205101A1 (en) 2007-12-13 2013-04-13 Improved immunizing composition

Publications (2)

Publication Number Publication Date
AU2008336295A1 AU2008336295A1 (en) 2009-06-18
AU2008336295B2 true AU2008336295B2 (en) 2013-07-11

Family

ID=40755754

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008336295A Ceased AU2008336295B2 (en) 2007-12-13 2008-12-12 Improved immunizing composition

Country Status (8)

Country Link
US (2) US20110020403A1 (enExample)
EP (1) EP2227249B1 (enExample)
JP (1) JP2011506433A (enExample)
CN (1) CN102026658A (enExample)
AU (1) AU2008336295B2 (enExample)
CA (1) CA2708260A1 (enExample)
NZ (1) NZ586367A (enExample)
WO (1) WO2009075646A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011059385A1 (en) * 2009-11-13 2011-05-19 Bengt Guss Immunizing composition for reducing streptococcal infections
US9333252B2 (en) 2010-05-26 2016-05-10 Intervacc Ab Vaccine against streptococcal infections based on recombinant proteins
EP2949340A1 (en) * 2014-05-30 2015-12-02 IDT Biologika GmbH Vaccine composition against Streptococcus suis infection
GB201502306D0 (en) 2015-02-12 2015-04-01 Hansa Medical Ab Protein
GB201502305D0 (en) 2015-02-12 2015-04-01 Hansa Medical Ab Protein
CN118562771A (zh) * 2020-06-18 2024-08-30 上海宝济药业股份有限公司 一种免疫球蛋白降解酶IdeE的突变体
EP4321178A4 (en) * 2021-04-05 2024-10-02 Lg Chem, Ltd. VACCINE COMPOSITION AGAINST CORONAVIRUS
JP2024547125A (ja) 2021-12-22 2024-12-26 上海宝済薬業股▲ふん▼有限公司 免疫グロブリン分解酵素ＩｄｅＥの変異体の用途
CN114437235B (zh) * 2022-01-04 2024-02-09 中国农业科学院哈尔滨兽医研究所（中国动物卫生与流行病学中心哈尔滨分中心） 马链球菌马亚种8种蛋白的重组融合蛋白及其制备方法和应用
WO2024108137A2 (en) 2022-11-18 2024-05-23 Seismic Therapeutic, Inc. Fc fusion molecules and uses thereof
JP2026501731A (ja) 2023-01-06 2026-01-16 サイズミック セラピューティク インコーポレイテッド プロテアーゼ変異体及びその使用
WO2025054602A1 (en) * 2023-09-08 2025-03-13 The Texas A&M University System Protein for the serological detection of streptococcus equi subspecies equi exposure or infection
CN118497176B (zh) * 2024-07-16 2025-01-21 苏州康聚生物科技有限公司 一种免疫球蛋白降解酶

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060140980A1 (en) * 2002-10-11 2006-06-29 Beng Guss Immunization of non-human mammals against streptococcus equi
US20070243195A1 (en) * 2006-03-29 2007-10-18 Minke Jules M Vaccine against streptococci

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR241545A1 (es) 1985-07-12 1992-08-31 Cornell Res Foundation Inc Un metodo para preparar una cepa de s. equi avirulenta a.t.c.c. 53186 para equinos.
US5583014A (en) 1990-07-03 1996-12-10 Bayer Corporation Preparation and use of enzyme-detergent extracted Streptococcus zoopidemicus vaccine
SE9003374D0 (sv) 1990-10-22 1990-10-22 Alfa Laval Agri Int A collagen binding protein as well as its preparation
SE9302855D0 (sv) 1993-09-06 1993-09-06 Martin Lindberg Method and means for producing plasmaproteinase inhibitor binding proteins
IES76925B2 (en) 1996-07-03 1997-11-19 Provost Subunit Vaccine for Streptococcus Equi
CA2243730C (en) * 1997-07-29 2009-12-22 Akzo Nobel N.V. Streptococcus equi vaccine
SE9804491D0 (sv) 1998-12-22 1998-12-22 Bengt Guss Novel fibronectin-binding protein
WO2000076540A2 (en) * 1999-06-10 2000-12-21 Med Immune, Inc. Streptococcus pneumoniae proteins and vaccines
US6887480B1 (en) 1999-06-10 2005-05-03 Medimmune, Inc. Streptococcus pneumoniae proteins and vaccines

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060140980A1 (en) * 2002-10-11 2006-06-29 Beng Guss Immunization of non-human mammals against streptococcus equi
US20070243195A1 (en) * 2006-03-29 2007-10-18 Minke Jules M Vaccine against streptococci

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Flock et al (2004) Infection and Immunity, June, 72(6):3228-3236 *
Flock et al (2006) Vaccine, May, 24(9):4144-4151 *
Waller et al (2007) Vaccine, April, 25(18):3629-3635 *

Also Published As

Publication number Publication date
US20110020403A1 (en) 2011-01-27
CA2708260A1 (en) 2009-06-18
JP2011506433A (ja) 2011-03-03
US9987342B2 (en) 2018-06-05
NZ586367A (en) 2012-04-27
WO2009075646A1 (en) 2009-06-18
CN102026658A (zh) 2011-04-20
EP2227249B1 (en) 2018-04-25
EP2227249A4 (en) 2011-08-31
US20140220064A1 (en) 2014-08-07
AU2008336295A1 (en) 2009-06-18
EP2227249A1 (en) 2010-09-15

Similar Documents

Publication Publication Date Title
US9987342B2 (en) Immunizing composition
US11814415B2 (en) Vaccine against S. suis infection
AU2011258898B2 (en) Vaccine against Streptococcal infections based on recombinant proteins
AU2015265884B2 (en) Vaccine composition against Streptococcus suis infection
JP2023503057A (ja) ヘモフィルス・パラスイスに対する新規ワクチン
JP7812328B2 (ja) ヘモフィルス・パラスイスに対する新規ワクチン
EP2646049B1 (en) Composition for immunization against streptococcus pneumoniae
JP2015509713A (ja) 線毛タンパク質および組成物
KR20200076551A (ko) 마이코플라즈마 폐렴 및 흉막폐렴 예방용 백신 조성물
CA2501621C (en) Immunization of non-human mammals against streptococcus equi
US20120225079A1 (en) Immunizing composition for reducing streptococcal infections
HK1156230A (en) Improved immunizing composition
BRAMBILA et al. Two outer membrane lipoproteins from histophilus somni are Immunogenic in rabbits and sheep and induce protection against bacterial challenge in mice
HK1183677B (en) Vaccine against streptococcal infections based on recombinant proteins
AU2013205101A1 (en) Improved immunizing composition

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired